Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate
US10351587B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10351587-B2 |
| Application number | US-201113022391-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 7, 2011 |
| Priority date | Mar 31, 2000 |
| Publication date | Jul 16, 2019 |
| Grant date | Jul 16, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of using 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate (I) and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.
First claim
Opening claim text (preview).
We claim as our invention: 1. A pharmaceutical composition comprising 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate and a pharmaceutically acceptable carrier, wherein a single dose of the pharmaceutical composition provides effective fertility suppression in a male patient in need thereof. 2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises an aqueous suspension vehicle. 3. The pharmaceutical composition of claim 1 , wherein the composition is a parenteral formulation. 4. The pharmaceutical composition of claim 1 , wherein the composition is a subcutaneous injectable formulation. 5. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises an oil. 6. The pharmaceutical composition of claim 5 , wherein the oil is castor oil. 7. The pharmaceutical composition of claim 1 , further comprising one or more steroidal progestins or estrogens. 8. The pharmaceutical composition of claim 1 , wherein a single dose of the pharmaceutical composition provides effective fertility suppression in a male patient in need thereof for at least one month. 9. The pharmaceutical composition of claim 1 , wherein a single dose of the pharmaceutical composition provides effective fertility suppression in a male patient in need thereof for at least six weeks. 10. The pharmaceutical composition of claim 1 , wherein a single dose of the pharmaceutical composition provides effective fertility suppression in a male patient in need thereof for at least two months. 11. The pharmaceutical composition of claim 1 , wherein a single dose of the pharmaceutical composition provides effective fertility suppression in a male patient in need thereof for at least three months. 12. A pharmaceutical composition comprising 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate and a pharmaceutically acceptable carrier, wherein a single dose of the pharmaceutical composition provides effective hormone therapy in a patient in need thereof. 13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable carrier comprises an aqueous suspension vehicle. 14. The pharmaceutical composition of claim 12 , wherein the composition is a parenteral formulation. 15. The pharmaceutical composition of claim 12 , wherein the composition is a subcutaneous injectable formulation. 16. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable carrier comprises an oil. 17. The pharmaceutical composition of claim 16 , wherein the oil is castor oil. 18. The pharmaceutical composition of claim 12 , further comprising one or more steroidal progestins or estrogens. 19. The pharmaceutical composition of claim 12 , wherein a single dose of the pharmaceutical composition provides effective hormone therapy in a patient in need thereof for at least one month. 20. The pharmaceutical composition of claim 12 , wherein a single dose of the pharmaceutical composition provides effective hormone therapy in a patient in need thereof for at least six weeks. 21. The pharmaceutical composition of claim 12 , wherein a single dose of the pharmaceutical composition provides effective hormone therapy in a patient in need thereof for at least two months. 22. The pharmaceutical composition of claim 12 , wherein a single dose of the pharmaceutical composition provides effective hormone therapy in a patient in need thereof for at least three months.
Assignees
Inventors
Classifications
of the sex hormones · CPC title
at position 3 · CPC title
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title
Oxiranes · CPC title
the substituent being an OH group free esterified or etherified · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10351587B2 cover?
- Methods of using 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate (I) and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.
- Who is the assignee on this patent?
- Blye Richard P, Kim Hyun K, Us Health
- What technology area does this patent fall under?
- Primary CPC classification C07J1/0059. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).